Point of Care Advertising: Reaching Patients When Decisions Are Made

Point of care advertising places brand messages in clinical settings, at the exact moment patients and healthcare providers are making treatment decisions. It works because the context is irreplaceable: a patient sitting in a waiting room or exam room is not scrolling past your ad. They are present, attentive, and often already thinking about the condition your product addresses.

That combination of timing, attention, and intent is difficult to replicate anywhere else in the media mix. Which is why point of care has moved from a niche healthcare tactic to a serious strategic channel for pharmaceutical, medical device, and health-adjacent brands.

If you are building a go-to-market strategy for a healthcare brand, point of care belongs in the conversation early. Not because it is fashionable, but because the commercial logic is sound. You can explore the broader strategic framework at The Marketing Juice Go-To-Market and Growth Strategy hub, where I cover channel strategy, audience targeting, and growth planning across sectors.

What Is Point of Care Advertising, Exactly?

Point of care advertising encompasses any brand communication that reaches patients or healthcare providers within a clinical environment. That includes digital screens in waiting rooms, exam room tablets, physician office posters, pharmacy counter displays, infusion center media, and electronic health record integrations that surface relevant messages during patient consultations.

The format has evolved considerably. Ten years ago, point of care largely meant printed brochures and static posters. Today it includes programmatic digital placements, condition-specific content targeting, and platforms that can serve different creative based on the specialty of the practice or the demographic profile of the patient population.

The core principle has not changed, though. You are putting a message in front of someone at the moment they are most receptive to it. A patient waiting to discuss a chronic condition with their doctor is not the same audience as someone watching a pharmaceutical ad during a television program. The context changes everything about how the message lands.

This is something I have come back to repeatedly across my career. Context is the variable that most media planning underweights. You can have the right audience, the right message, and the wrong moment, and the ad does almost nothing. Point of care collapses that gap between message and moment in a way that very few channels can.

Who Uses Point of Care Advertising and Why?

The primary users are pharmaceutical companies, particularly those marketing prescription medications where physician recommendation and patient awareness both matter. Brands managing conditions like diabetes, hypertension, mental health, oncology, and autoimmune disorders have been heavy investors in the channel for years.

Medical device companies use it to influence both patient preference and physician familiarity. Health insurance brands, particularly those marketing Medicare Advantage plans, have increased their point of care spend significantly as competition in that category has intensified. And increasingly, consumer health brands, including over-the-counter products and health technology companies, are exploring the channel as they look for environments where health-mindset audiences are concentrated.

The common thread is that these brands are not just trying to generate awareness. They are trying to influence a specific behaviour: a conversation between patient and provider, a prescription decision, a product trial, or a plan selection. That is a different brief than most brand advertising, and it requires a different channel logic.

I spent time working with clients in financial services and professional services sectors where the sales cycle was long and the decision-making environment was equally specific. The principle that emerged was the same one that applies to point of care: the closer you can get your message to the actual decision moment, the more efficiently your media spend works. If you are interested in how that logic applies in regulated industries more broadly, B2B financial services marketing covers the parallel dynamics in some depth.

How Does the Targeting Actually Work?

Modern point of care platforms have become considerably more sophisticated than their origins suggest. The major networks, including companies like Outcome Health, PatientPoint, and Veeva Engage, have built infrastructure that allows targeting by medical specialty, geographic market, practice size, and in some cases patient condition data derived from EHR integrations.

This means a brand marketing a rheumatology treatment can target placements specifically in rheumatology practices, rather than paying for broad clinical reach across all specialties. A brand focused on a regional market can concentrate spend geographically. A pharmaceutical company launching in a competitive category can prioritise practices where the target condition is frequently diagnosed.

The EHR-integrated formats are particularly interesting from a targeting standpoint. When a physician pulls up a patient record for a condition your product addresses, some platforms can surface relevant clinical information or branded content at that moment. The regulatory and ethical boundaries around this are tightly governed, but the targeting precision it enables is meaningfully better than anything available through conventional media.

That said, I would encourage anyone evaluating point of care to apply the same rigour they would to any data-driven channel. Digital marketing due diligence matters here, particularly around how audience data is sourced, how targeting claims are verified, and what the actual reach looks like versus what is being sold. The healthcare data ecosystem has a history of overclaiming, and buyers should push vendors on specifics.

What Makes the Channel Genuinely Different from Endemic Advertising?

There is some conceptual overlap between point of care and endemic advertising, which places brand messages within content environments that are topically relevant to the product category. A pharmaceutical brand advertising on a health information website is endemic. A pharmaceutical brand advertising in a cardiology practice waiting room is point of care.

The distinction matters because the audience state is different. Endemic advertising reaches people who are interested in a health topic, but that interest is diffuse. They might be researching a condition out of curiosity, managing something minor, or reading on behalf of a family member. Point of care reaches people who are physically present in a clinical environment for a specific reason. The signal is much stronger.

The analogy I keep returning to is the difference between someone browsing a clothes shop online and someone standing in the changing room with a garment in their hands. Both are interested. One is ten times more likely to buy. Point of care is the changing room. Endemic advertising is the browsing. Both have a role, but they are doing different jobs and should be evaluated differently.

This is also why I am sceptical when brands treat point of care as an awareness channel and measure it accordingly. Awareness is the wrong frame. The channel is better understood as a decision-support environment, and the metrics should reflect that.

How Do You Measure Point of Care Effectiveness?

Measurement is the honest challenge in this channel, and anyone who tells you otherwise is either oversimplifying or selling something.

The most commonly used metric is script lift, which measures whether prescriptions for the advertised product increased in practices exposed to the campaign compared to a matched control group. When done properly, with well-matched control groups and sufficient sample sizes, script lift studies can provide a credible read on commercial impact. The methodology is not perfect, but it is directionally useful.

Patient-reported outcomes are also used, typically through surveys that capture whether patients recall seeing information about a treatment and whether it influenced their conversation with their physician. These are softer measures but they capture something script lift misses, which is the patient’s role in initiating the conversation.

The harder problem is attribution across a full campaign. A patient who sees a television ad, visits a brand website, sees a point of care display in their doctor’s office, and then fills a prescription, has been touched by multiple channels. Isolating the contribution of any single touchpoint is genuinely difficult, and I have seen brands both over-credit and under-credit point of care depending on which methodology they applied.

My view, shaped by years of managing large media budgets and watching attribution models contradict each other, is that the goal should be honest approximation rather than false precision. If the channel is directionally working, if script lift is positive, if patient recall is strong, if the cost per influenced script compares favourably to other channels, that is a sufficient basis for continued investment. Demanding a level of measurement certainty that the channel cannot deliver is a reason to avoid good decisions, not a rigorous standard.

When I judged at the Effie Awards, one of the consistent patterns in losing entries was measurement frameworks that were either too narrow or too ambitious. The best work was clear about what it was measuring and honest about what it was not. Point of care campaigns benefit from the same discipline.

What Does a Well-Structured Point of Care Campaign Look Like?

The campaigns that perform well share a few structural characteristics that are worth naming clearly.

First, they are integrated with the broader media plan rather than siloed. Point of care works best when it is reinforcing messages that patients have already encountered through DTC television, digital, or social. The clinical environment is not the right place to introduce a brand for the first time. It is the right place to deepen familiarity and prompt a conversation that has been primed elsewhere.

Second, the creative is calibrated for the environment. Waiting room content needs to work without audio, needs to be readable at a distance, and needs to communicate clearly to someone who may be anxious, distracted, or unfamiliar with medical terminology. Exam room content can be more detailed and more condition-specific because the patient is in a different headspace. These are not the same creative brief.

Third, the targeting is aligned with the actual patient experience. A brand treating a condition that requires specialist referral should prioritise primary care environments where the referral conversation happens, not just specialist practices where the treatment decision is confirmed. Getting the targeting wrong at this level is a structural error that no amount of creative quality can fix.

Fourth, there is a clear conversion pathway. What do you want the patient to do after seeing the ad? Ask their doctor about the treatment. Request a brochure. Visit a website. Download a patient support program. The call to action needs to be specific and achievable within the clinical context, not a generic brand awareness prompt. This connects to the broader question of how you structure your lead and conversion architecture, which is something I cover in the context of pay per appointment lead generation for brands where the consultation itself is the critical conversion event.

Where Does Point of Care Fit in a Broader Go-To-Market Strategy?

This is the question I find most interesting, and also the one that gets the least careful treatment in most media planning conversations.

Point of care is not a standalone channel. It is a component of a coordinated system that should include DTC media, HCP-directed promotion, digital education, and wherever appropriate, patient support programs. The channel’s job is to close the loop between awareness and action at the moment when action is most possible.

For brands with complex product portfolios or multiple business units, the coordination challenge is real. A corporate-level campaign driving broad condition awareness needs to connect logically with a brand-level point of care execution that prompts a specific treatment conversation. Those two things need to feel coherent to the patient, even if they are managed by different teams with different budgets. The corporate and business unit marketing framework I have written about separately is directly relevant here, particularly for larger pharmaceutical companies where brand teams operate with significant autonomy.

The strategic question is also about where in the funnel point of care delivers the most value. My honest assessment is that it is strongest in the middle and lower funnel, where patients are condition-aware but not yet treatment-committed. It is less effective at the very top of the funnel, where the job is to build condition awareness among people who do not yet know they have a problem, and less critical at the very bottom, where the patient has already made a decision and just needs support executing it.

That middle-funnel positioning has implications for how you allocate budget across channels. If you are underinvesting in top-of-funnel condition education, point of care will have a smaller pool of primed patients to convert. If you are underinvesting in patient support programs, you may convert patients at the point of care but lose them at adherence. The channel does not exist in isolation, and the budget allocation decisions around it should reflect that.

One useful exercise before committing to a point of care buy is to audit your existing digital presence against the patient experience. I have seen brands invest heavily in clinical environments while their website does almost nothing to support the patient who goes home and searches for more information after the appointment. A website analysis checklist is a simple but often overlooked step that can reveal significant gaps in the conversion pathway that point of care is supposed to feed.

The broader growth strategy context also matters. Point of care is most valuable for brands that are trying to grow within an existing category, converting patients from competitor treatments or from no treatment at all, rather than brands trying to create a new category from scratch. Market penetration strategy and point of care share a natural alignment: both are focused on converting available demand rather than creating new demand from scratch.

For brands that are genuinely trying to expand a category, the investment calculus is different. You need broader reach and more sustained education before the clinical environment becomes the right place to close. That does not mean avoiding point of care, but it does mean sequencing it correctly within a longer campaign architecture. Forrester’s intelligent growth model is a useful reference for thinking about how to sequence investment across a growth strategy, even if the specific context is different from healthcare.

The Innovation Trap in Point of Care

I want to address something that comes up regularly when brands and agencies discuss point of care: the temptation to innovate for its own sake.

I have sat in briefing rooms where the ask was for something “innovative” in the clinical environment, without any clear definition of what problem the innovation was supposed to solve. Interactive exam room tablets with gamified condition education. Augmented reality displays in waiting rooms. AI-driven content personalisation based on patient demographics. Some of these ideas have genuine merit. Most of them are solutions looking for a problem.

The question I always ask is: what does this do for the patient or the physician that a well-executed conventional execution does not? If the answer is vague, the innovation is probably theatre. A clear, well-placed, condition-relevant message in a waiting room will outperform a gimmicky interactive experience that confuses or distracts. The clinical environment is not the place to experiment with formats that have not been tested. The stakes are too high and the audience too specific.

This is not an argument against evolving the channel. Digital point of care has genuinely improved on static print in terms of targeting, measurement, and creative flexibility. EHR integrations have opened up targeting precision that was not previously possible. Those are real improvements tied to real commercial problems. The test is always whether the innovation solves something, not whether it impresses a client in a pitch room.

Scaling any channel, including point of care, requires the same discipline. BCG’s research on scaling effectively applies here: the brands that grow their point of care investment successfully are the ones that nail the fundamentals first, then expand. The ones that fail are usually the ones that scaled before they had a repeatable model.

If you are working through a broader growth strategy for a healthcare brand, the principles that govern channel selection, sequencing, and measurement are covered in more depth across The Marketing Juice Go-To-Market and Growth Strategy hub. Point of care is one piece of a larger system, and the decisions around it are better made with a clear strategic framework behind them.

What to Ask Before You Buy

Before committing budget to any point of care network, there are five questions worth pressing vendors on.

First, what is the verified reach in the specific specialty and geography you need? Total network reach numbers are often impressive and largely irrelevant. What matters is how many of the right practices are in the network.

Second, how is the audience data sourced and how current is it? Practice-level data in healthcare changes frequently. Networks that are not maintaining their data actively will deliver targeting that looks precise but is not.

Third, what measurement methodology do they use for script lift, and can you see the control group construction? This is where a lot of the commercial claims in point of care fall apart under scrutiny. A vendor who cannot explain their methodology clearly is a vendor whose results you should not trust.

Fourth, what are the compliance and regulatory guardrails, particularly for EHR-integrated formats? The FDA’s oversight of pharmaceutical promotion in digital environments is evolving, and the last thing a brand needs is a point of care execution that creates regulatory exposure.

Fifth, what does the creative production process look like, and who is responsible for ensuring it meets clinical environment standards? This sounds operational but it matters. Creative that works on a television screen often fails in an exam room, and the vendor should have a clear view on what performs in their environment.

These are not difficult questions, but they separate vendors who have thought carefully about their product from those who are selling a concept. The discipline of asking them is part of what I would call genuine go-to-market rigour, applied to channel selection rather than brand strategy.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions